South Korea Car-T Cell Therapy Market is Segmented By Targeted Antigen (CD19, CD20, BCMA, GCP-3, Claudin 18.2), By Therapeutic Application (B-cell non....
Market Size in USD
CAGR16.1%
Study Period | 2024 - 2031 |
Base Year of Estimation | 2023 |
CAGR | 16.1% |
Market Concentration | Medium |
Major Players | Novartis AG, Pfizer, Inc., Bristol Myers Squibb, CARsgen Therapeutics Co., Ltd., Fate Therapeutics, Inc. |
The South Korea Car-T Cell Therapy Market is estimated to be valued at USD 7.88 Mn in 2024 and is expected to reach USD 18.91 Mn by 2031, growing at a compound annual growth rate (CAGR) of 16.1% from 2024 to 2031.
With successful treatment of hematologic malignancies and rising investment by both public and private players in developing CAR-T therapies, the market is expected to witness steady growth.